Last checked at 9 Dec 2019 13:10
hVIVO plc
("hVIVO or the "Company")
Total Voting Rights
At 9 December 2019 the Company's capital consisted of 83,293,129 ordinary shares of 5 pence each in issue with International Securities Identification Number GB00B6ZM0X53. This figure (83,293,129) may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
For further information please contact:
hVIVO plc | +44 (0)20 7756 1300 |
Anesh Patel, Interim Finance Director and Company Secretary | |
Fleur Wood, EVP, Investor Relations & Communications | |
Numis Securities Limited (Nominated Adviser) | +44 (0)20 7260 1000 |
Freddie Barnfield / Huw Jeremy | |
FTI Consulting (Financial PR) | +44 (0)20 3727 100 |
Simon Conway / Victoria Foster Mitchell |
Notes to Editors:
hVIVO plc is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.